Literature DB >> 8609341

Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival.

P R Rickenbacher1, P T Trindade, G A Haywood, R H Vagelos, J S Schroeder, K Willson, L Prikazsky, M B Fowler.   

Abstract

OBJECTIVES: This study sought to assess the clinical characteristics and survival of patients with symptomatic heart failure who were referred as potential heart transplant candidates, but were selected for medical management.
BACKGROUND: Patients with severe left ventricular dysfunction referred for heart transplantation may be considered too well to be placed immediately on an active waiting transplant list. The clinical characteristics of this patient group and their survival have not been well defined. These patients represent a unique group that are characterized by comparatively low age and freedom from significant comorbid conditions.
METHODS: We studied 116 consecutive patients with symptomatic heart failure, severe left ventricular dysfunction (left ventricular ejection fraction 20 +/- 7% [mean +/- SD]) and duration of symptoms >1 month referred for heart transplantation, who were acceptable candidates for the procedure but who were not listed for transplantation because of relative clinical stability. These patients were followed up closely on optimal medical therapy. A variety of baseline clinical, hemodynamic and exercise variables were assessed to define this patient group and used to predict cardiac death and requirement later for heart transplantation.
RESULTS: During a mean follow-up period of 25.0 +/- 14.8 months (follow-up 99% complete), there were eight cardiac deaths (7%) (seven sudden, one acute myocardial infarction). Only nine patients (8%) were listed for heart transplantation. Actuarial 1- and 4-year cardiac survival rates were 98 +/- 1% and 84 +/- 7% (mean +/- SE), respectively, and freedom from listing for transplantation was 95 +/- 2% and 84 +/- 7% (mean +/- SE), respectively. Patients were mainly in New York Heart Association functional class II or III and had a preserved cardiac index (2.4 liters/min.m2), pulmonary capillary wedge pressure of 16 +/- 9 mm Hg (mean +/- SD) and maximal oxygen consumption of 17.4 +/- 4.3 ml/min per kg (mean +/- SD). By logistic regression analysis, there was no predictor for cardiac death. Longer duration of heart failure (p = 0.013) and mean pulmonary artery (p < 0.05) and pulmonary systolic (p = 0.014) and diastolic (p < 0.05) pressures correlated significantly with listing for heart transplantation by univariate logistic regression. By multivariate logistic regression, only pulmonary artery systolic pressure (p < 0.004) and duration of heart failure (p < 0.015) remained as predictors for need for later transplantation.
CONCLUSIONS: In the current treatment era, prognosis is favorable in a definable group of transplant candidates despite severe left ventricular dysfunction. This patient group can be identified after intensive medical therapy by stable symptoms, a relatively high maximal oxygen uptake at peak exercise and a preserved cardiac output.

Entities:  

Mesh:

Year:  1996        PMID: 8609341     DOI: 10.1016/0735-1097(95)00587-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Pulmonary hypertension with left-sided heart disease.

Authors:  Marco Guazzi; Ross Arena
Journal:  Nat Rev Cardiol       Date:  2010-10-05       Impact factor: 32.419

Review 2.  Predicting survival in heart failure.

Authors:  Viorel G Florea; Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

3.  Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification.

Authors:  L C Davies; D P Francis; M Piepoli; A C Scott; P Ponikowski; A J Coats
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

Review 4.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

5.  Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure.

Authors:  T M Ramahi; M D Longo; K Rohlfs; N Sheynberg
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

Review 6.  The Role of Cardiac Imaging in Heart Failure with Reduced Ejection Fraction.

Authors:  Rebecca C Gosling; Abdallah Al-Mohammad
Journal:  Card Fail Rev       Date:  2022-06-24

7.  I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes.

Authors:  Denilson Campos de Albuquerque; João David de Souza Neto; Fernando Bacal; Luiz Eduardo Paim Rohde; Sabrina Bernardez-Pereira; Otavio Berwanger; Dirceu Rodrigues Almeida
Journal:  Arq Bras Cardiol       Date:  2015-04-03       Impact factor: 2.000

8.  Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.

Authors:  Jeffrey S Tran; Ofer Havakuk; Jennifer M McLeod; Jennifer Hwang; Hoi Yan Kwong; David Shavelle; Michael R Zile; Uri Elkayam; Michael W Fong; Luanda P Grazette
Journal:  ESC Heart Fail       Date:  2021-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.